Global Access Program

Working hand in hand to provide innovative diagnostic solutions to those who need it most

Working hand in hand to provide innovative diagnostic solutions to those who need it most

More than 35 million people are currently living with HIV

Universal access to quality healthcare and medical innovation remains a global challenge. To address this challenge, many of the world’s top relief and aid organisations have joined together with an ambitious goal: ending the HIV/AIDS pandemic.

As the leading provider of HIV viral load testing, Roche created the Global Access Program to contribute to the UNAIDS 90-90-90 goal, expanding access to quality, sustainable diagnostic testing for countries hardest hit by HIV.

Working hand in hand to provide innovative diagnostic solutions to those who need it mos

"We applaud all the global partners who came together to ensure that over 31 million people living with HIV/AIDS in low- and middle-income countries will be able to access viral load testing at this reduced price."


President Bill Clinton, Chairman of the Clinton Health Access Initiative

"We welcome this significant price breakthrough – the urgent call of people living with HIV is being answered. Now, with viral load testing, we can help ensure HIV treatment improves quality of life."


Michel Sidibé, UNAIDS Executive Director


cobas® Plasma Separation Card

Redefine the reach of reliable testing. The cobas® Plasma Separation Card makes reliable, quantitative HIV testing more accessible to those in the remote areas.

Sign up to receive regular updates about the Global Access Program.
Contact us

90-90-90 lays the groundwork for achieving global HIV viral suppression


By 2020...


*Adults and children estimated to be living with HIV in 2014 and 2020, assuming infection rates remain the same.

Targeting 90-90-90 with optimized diagnostic testing


The Global Access Program contributes to the goals of 90-90-90 by providing diagnostic products for early infant diagnosis and viral load testing.


Early Infant Diagnosis

Early diagnosis in infants and young children is a major challenge—antibody tests are ineffective due to maternal antibodies remaining in the child. The Roche HIV Qualitative assay provides reliable, accurate information on whether or not an infant is infected.

RMD_Virology_Early Infant Diagnostics
Dry blood spot


The use of dried blood spots is an increasingly sustainable solution which allows for PCR testing. Collecting small blood on a specially designed collection card facilitates easy sample transportation and storage, and is ideal for resource-limited areas.

GAP lower image
Learn more about the critical importance of early infant diagnosis.


Viral Load Testing

Roche is a global market leader in HIV viral load testing, a method for determining the amount of HIV circulating in a body. Testing for viral load can confirm if patients are responding to medication, or if second-line therapies should be considered.

GAP lower image



Our partners



UNAIDS is working to end the AIDS epidemic by 2030.

Learn More

Clinton Health Access Initiative


CHAI was founded to help the lives of millions of people living with HIV/AIDS in the developing world.

Learn more

The Global Fund


Accelerating the end of AIDS, tuberculosis, and malaria as epidemics.

Learn More
  1. UNAIDS Core Epidemiology Slides, July 2015. sites/default/files/media_asset/20150714_epi_core_en.pdf. Accessed June 13, 2016.
  2. UNAIDS Report on the global AIDS epidemic. 2010. Accessed June 13, 2016.
  3. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. 2014. unaids/contentassets/documents/unaidspublication/ 2014/90-90-90_en.pdf. Accessed June 13, 2016.
  4. Pavia AT. Primary care of infants and children with HIV. http:// Accessed June 13, 2016.
  5. UNAIDS 2013 | AIDS by the numbers. default/files/media_asset/ JC2571_AIDS_by_the_numbers_en_1.pdf. Accessed June 13, 2016.